MI risk is best captured by number of apoB-containing lipoproteins - PACE-CME

MI risk is best captured by number of apoBcontaining lipoproteins

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

The remaining challenges in lowering LDL-c in patients at increased CV risk
The remaining challenges in lowering LDL-c in patients at increased CV risk
MinuteCE®
The remaining challenges in lowering LDL-c in patients at increased CV risk
0.75 program credits
- Prof. Kausik Ray
0.75 program credits
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
MinuteCE®
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
0.75 program credits
- Ulrich Laufs, MD, PhD
0.75 program credits
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
MinuteCE®
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
0.75 program credits
- Pasquale Perrone-Filardi, MD, PhD
0.75 program credits
Understanding the role of triglycerides in the assessment of residual risk
Understanding the role of triglycerides in the assessment of residual risk
MinuteCE®
Understanding the role of triglycerides in the assessment of residual risk
0.50 program credits
- Prof. Alberto Zambon MD, PhD, FAHA
0.50 program credits